authors
- Moore, K
- Oza, A
- Colombo, N
- Oaknin, A
- Scambia, G
- Lorusso, D
- Farias-Eisner, R
- Banerjee, S
- Murphy, C
- Tanyi, J
- Hirte, Holger
- Konner, J
- Lim, P
- Hayes, M Prasad
- Monk, B
- Kim, S
- Wang, J
- Pautier, P
- Vergote, I
- Birrer, M
FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- October 2019
has subject area
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Annals of Oncology Journal